Esôfago de Barrett é uma condição na qual ocorre uma alteração anormal (metaplásica) nas células da mucosa que revestem a parte inferior do esôfago. As células mudam de epitélio escamoso estratificado para epitélio colunar simples, intercalado com células caliciformes que normalmente são encontradas apenas no intestino delgado e no intestino grosso. Essa alteração é considerada uma condição pré-maligna devido ao seu potencial de transição para adenocarcinoma esofágico, um câncer muitas vezes fatal.
Introdução
O que você precisa saber de cara
Visão geral
A displasia de alto grau em doentes com esôfago de Barrett é uma condição na qual as células que revestem o esôfago (o tubo que liga a boca ao estômago) apresentam alterações significativas, consideradas pré-cancerosas. O esôfago de Barrett é uma condição pré-existente, na qual o revestimento normal do esôfago é substituído por um tecido semelhante ao do intestino, geralmente como consequência de refluxo gastroesofágico crônico. A displasia de alto grau representa o estágio mais avançado dessas alterações celulares, com maior risco de progressão para câncer de esôfago. A prevalência estimada é de 1 a 5 casos para cada 10.000 pessoas.[1][2]
Sinais e sintomas
Os principais sinais e sintomas associados a esta condição incluem: esôfago de Barrett (a condição de base), disfagia (dificuldade para engolir), obstrução esofágica (sensação de alimento parado no peito) e refluxo gastroesofágico (azia e regurgitação ácida). É importante notar que a displasia de alto grau em si pode não causar sintomas adicionais, sendo frequentemente detectada durante exames de vigilância em pessoas com esôfago de Barrett.[1][2]
Causas genéticas
Até o momento, não há um gene específico identificado como causa direta da displasia de alto grau em doentes com esôfago de Barrett. A condição não é considerada hereditária no sentido clássico (herança não aplicável). As alterações celulares ocorrem ao longo do tempo, principalmente devido à exposição crônica ao ácido do estômago (refluxo gastroesofágico), que danifica o revestimento do esôfago e leva a mutações adquiridas (somáticas) nas células.[1][3]
Diagnóstico
O diagnóstico da displasia de alto grau é feito por meio de endoscopia digestiva alta com biópsia do esôfago. Durante o exame, o médico coleta pequenas amostras do tecido do esôfago de Barrett, que são analisadas ao microscópio por um patologista. A displasia de alto grau é classificada quando as células apresentam alterações marcantes em sua aparência e organização, indicando um risco elevado de progressão para câncer. Não há testes genéticos específicos (germinativos) recomendados para o diagnóstico, pois a condição não é causada por uma mutação hereditária.[1][3]
Tratamento e manejo
O manejo da displasia de alto grau em doentes com esôfago de Barrett é focado na prevenção da progressão para câncer de esôfago. As opções de tratamento incluem vigilância endoscópica rigorosa (endoscopias frequentes com biópsias) e procedimentos de ablação (como ablação por radiofrequência) ou ressecção endoscópica da área afetada. O controle do refluxo gastroesofágico com medicamentos (como inibidores da bomba de prótons) é fundamental para reduzir a irritação contínua do esôfago. A decisão sobre o tratamento deve ser individualizada, discutida com uma equipe médica especializada. Não há cobertura específica pelo Sistema Único de Saúde (SUS) para esta condição.[1]
Prognóstico e qualidade de vida
O prognóstico depende do estágio em que a displasia é detectada e da resposta ao tratamento. Quando identificada precocemente e tratada adequadamente, a progressão para câncer pode ser prevenida ou retardada na maioria dos casos. A qualidade de vida pode ser impactada pela necessidade de exames endoscópicos frequentes e pelo manejo dos sintomas de refluxo. O acompanhamento regular com um gastroenterologista é essencial para monitorar a condição e ajustar o tratamento conforme necessário.[1]
Conteúdo informativo gerado e mantido automaticamente a partir de fontes oficiais (Orphanet, HPO, OMIM, SUS). Não substitui avaliação médica.
A **displasia de alto grau em doentes com esôfago de Barrett** é uma alteração celular avançada identificada na parede do esôfago. Ela costuma causar sintomas como **refluxo gastroesofágico** (sensação de queimação pelo retorno de ácido), **disfagia** (dificuldade de engolir) e **obstrução esofágica** (sensação de entalo). No Brasil, a condição não consta na lista oficial de PCDT de doenças raras e não possui medicamentos específicos fornecidos pelo SUS, devendo ser acompanhada nos serviços de referência da rede pública.
Esôfago de Barrett é uma condição na qual ocorre uma alteração anormal (metaplásica) nas células da mucosa que revestem a parte inferior do esôfago. As células mudam de epitélio escamoso estratificado para epitélio colunar simples, intercalado com células caliciformes que normalmente são encontradas apenas no intestino delgado e no intestino grosso. Essa alteração é considerada uma condição pré-maligna devido ao seu potencial de transição para adenocarcinoma esofágico, um câncer muitas vezes fatal.
Tem tratamento?
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 4 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Nenhum gene associado encontrado
Os dados genéticos desta condição ainda estão sendo catalogados.
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Displasia de alto grau em doentes com esôfago de Barrett
Centros de Referência SUS
24 centros habilitados pelo SUS para Displasia de alto grau em doentes com esôfago de Barrett
Centros para Displasia de alto grau em doentes com esôfago de Barrett
Detalhes dos centros
Hospital Universitário Prof. Edgard Santos (HUPES)
R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808
Serviço de Referência
Hospital Infantil Albert Sabin
R. Tertuliano Sales, 544 - Vila União, Fortaleza - CE, 60410-794 · CNES 2407876
Serviço de Referência
Hospital de Apoio de Brasília (HAB)
AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456
Serviço de Referência
Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)
Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207
Serviço de Referência
Hospital das Clínicas da UFG
Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424
Serviço de Referência
Hospital Universitário da UFJF
R. Catulo Breviglieri, Bairro - s/n - Santa Catarina, Juiz de Fora - MG, 36036-110 · CNES 2297442
Atenção Especializada
Hospital das Clínicas da UFMG
Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167
Serviço de Referência
Hospital Universitário Julio Müller (HUJM)
R. Luis Philippe Pereira Leite, s/n - Alvorada, Cuiabá - MT, 78048-902 · CNES 2726092
Atenção Especializada
Hospital Universitário João de Barros Barreto
R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878
Serviço de Referência
Hospital Universitário Lauro Wanderley (HULW)
R. Tabeliao Estanislau Eloy, 585 - Castelo Branco, João Pessoa - PB, 58050-585 · CNES 0002470
Atenção Especializada
Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)
R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647
Serviço de Referência
Hospital Pequeno Príncipe
R. Des. Motta, 1070 - Água Verde, Curitiba - PR, 80250-060 · CNES 3143805
Serviço de Referência
Hospital Universitário Regional de Maringá (HUM)
Av. Mandacaru, 1590 - Parque das Laranjeiras, Maringá - PR, 87083-240 · CNES 2216108
Atenção Especializada
Hospital de Clínicas da UFPR
R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980
Serviço de Referência
Hospital Universitário Pedro Ernesto (HUPE-UERJ)
Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221
Serviço de Referência
Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)
Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988
Serviço de Referência
Hospital São Lucas da PUCRS
Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928
Serviço de Referência
Hospital de Clínicas de Porto Alegre (HCPA)
Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601
Serviço de Referência
Hospital Universitário da UFSC (HU-UFSC)
R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356
Serviço de Referência
Hospital das Clínicas da FMUSP
R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485
Serviço de Referência
Hospital de Base de São José do Rio Preto
Av. Brg. Faria Lima, 5544 - Vila Sao Jose, São José do Rio Preto - SP, 15090-000 · CNES 2079798
Atenção Especializada
Hospital de Clínicas da UNICAMP
R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223
Serviço de Referência
Hospital de Clínicas de Ribeirão Preto (HCRP-USP)
R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187
Serviço de Referência
UNIFESP / Hospital São Paulo
R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689
Serviço de Referência
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Pesquisa e ensaios clínicos
Nenhum ensaio clínico registrado para esta condição.
Publicações mais relevantes
The Impact of Hiatus Hernia Size on Dysplasia Progression in Patients With Barrett's Esophagus.
Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma, a condition with high morbidity and mortality and rapidly rising incidence in the Western population. Hiatus hernias increase exposure to acid and bile in the esophagus, driving epithelial damage that eventually leads to BE and dysplasia. Evidence is limited regarding the influence of hiatus hernias on dysplasia progression in BE, particularly in the modern era of endoscopy. We conducted a retrospective analysis of a prospectively maintained database, including patients undergoing surveillance endoscopy for BE at a single Australian tertiary center from 1999 to 2025. Endoscopic and histological data were recorded from all surveillance endoscopies and stratified according to the presence and size of hiatus hernia. A total of 547 patients with BE were included, of whom 72.8% were male. 46.6% (n = 255) had a hiatus hernia measuring ≥ 3 cm. Progression of dysplasia during the study period was more common in those with a ≥ 3 cm hiatus hernia (13.7% vs. 3.8%; HR 3.12, p = 0.001), as was progression to at least high-grade dysplasia (10.2% vs. 1.6%; HR 2.65, p = 0.012). There was a corresponding reduction in progression-free survival in the ≥ 3 cm hiatus hernia group (128 months vs. 189, p < 0.001). Hiatus hernias, particularly those measuring ≥ 3 cm, significantly increase the likelihood of dysplasia progression in BE. Patients with ≥ 3 cm hiatus hernias should be considered high risk when undertaking endoscopic treatment and surveillance. Further research is required to establish the role of antireflux surgery in parallel with resection and eradication therapy.
Adjunctive Use of p53 Immunohistochemistry for Risk Stratification in Barrett's Esophagus: A Systematic Review and Meta-Analysis.
The adjunctive use of p53 immunohistochemistry (IHC) has been proposed as a potential tool to improve risk stratification in Barrett's esophagus (BE) with conflicting results. We performed a systematic review and meta-analysis to evaluate the performance of p53 in predicting progression to advanced neoplasia [high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC)] among patients with BE. We searched multiple databases for studies that evaluated the use of aberrant p53 in esophageal biopsies among BE patients and reported progression rates to HGD/EAC. The outcomes were p53 test characteristics and incidence and risk ratio (RR) for progression to HGD/EAC in patients with and without aberrant p53 using random effects models. Among the 27 included studies, the proportion of patients with aberrant p53 expression at baseline was 20% (95% CI: 14%, 27%). The rate of progression with and without aberrant p53 was 8 per 100 person-years (95% CI: 6, 11) and 0.3 per 100 person-years (95% CI: 0.1, 0.6), respectively. Compared to patients without aberrant p53 expression, those with aberrant p53 had a higher risk for progression to HGD/EAC in cohort studies [RR = 10.2 (95% CI: 6.9, 15.0)] and case control studies [RR = 3.3 (95% CI: 2.5, 4.4)]. The sensitivity for progression for NDBE and low-grade dysplasia/indefinite for dysplasia was 42% and 77% and specificity was 96% and 76%, respectively. While aberrant p53 expression has been associated with an increased risk of progression to advanced neoplasia in BE patients undergoing surveillance, the diagnostic characteristics are suboptimal precluding uniform clinical adoption. Prospective studies with standardized grading protocols are needed to determine whether p53-guided surveillance strategies can meaningfully improve patient outcomes.
Clinical Utility of Biomarkers for Barrett's Esophagus: Guidelines and Future Directions.
Barrett's esophagus (BE) is a major risk factor for the development of esophageal adenocarcinoma (EAC) and is the only known precursor lesion for this lethal cancer. Although BE is relatively common among patients with gastroesophageal reflux disease, most patients with BE will never progress to EAC. Moreover, the cadence of progression from nondysplastic BE to dysplasia to EAC may be variable. The histologic grading of dysplasia during endoscopy is the most widely used prognosticator for risk stratification and management of BE based on its stepwise progression from low-grade dysplasia to high-grade dysplasia to mucosal EAC, and finally, to invasive EAC.
A machine-learning informed circulating microbial DNA signature for early diagnosis of esophageal adenocarcinoma.
Esophageal adenocarcinoma (EAC) has seen a dramatic rise in incidence in developed countries over the past three decades. Early detection of its precursors-gastroesophageal reflux disease (GERD), Barrett's esophagus (BE), and high-grade dysplasia (HGD) is critical for cancer prevention. This study presents the development and validation of a novel liquid biopsy assay based on circulating microbial DNA (cmDNA) for the early detection of EAC and HGD. Using metagenomic sequencing, we identified significant differences in microbial diversity and composition between EAC and HGD patients, as well as between BE and GERD patients. A total of 46 microbial candidates in tissue and 419 in serum were upregulated in EAC & HGD, with 11 consistently elevated in both sample types. Following qRT-PCR validation and LASSO regression, a 6-marker cmDNA panel was selected. This signature was incorporated into a diagnostic model trained with the XGBoost algorithm, achieving an AUC of 0.93 in the training cohort (52 HGD & EAC cases vs. 54 BE & GERD controls). Importantly, the model demonstrated robust performance in an independent testing cohort (23 HGD & EAC cases vs. 22 BE & GERD controls), yielding AUCs of 0.91 for EAC and 0.88 for HGD. These findings highlight the diagnostic potential of cmDNA-based profiling and support its utility as a minimally invasive, accurate, and generalizable tool for early detection of esophageal adenocarcinoma.
The Tissue Systems Pathology Test Predicts Risk of Progression in Patients With Barrett's Esophagus: Systematic Review and Meta-Analysis.
A systematic review and meta-analysis of published clinical validity studies was conducted to evaluate the predictive performance of the TSP-9 test. Identifying patients with Barrett's esophagus (BE) who will progress to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) is challenging. The tissue systems pathology (TSP-9) test can predict risk of progression to HGD/EAC in BE patients. Databases were searched for studies that assessed the clinical validity of TSP-9, and data describing progressors, non-progressors, TSP-9 results, and hazard ratios (HR) with 95% confidence intervals (CIs) were extracted. Odds ratios (OR), sensitivity, specificity, and prevalence-adjusted positive and negative predictive values (PPV adj /NPV adj ) were calculated and used for meta-analysis. Six studies met eligibility criteria, comprising 699 patients. ORs and HRs for TSP-9 had mean common effect size estimates of 6.52 (95% CI: 4.40-9.66, P <0.0001, I2 =33%) and 6.66 (95% CI: 4.59-9.66, P <0.0001, I2 =0%), respectively, for predicting progression to HGD/EAC. Mean common effect size estimates were 61% (95% CI: 54%-68%) for sensitivity, 81% (95% CI: 78%-84%) for specificity, 28% (95% CI: 17%-42%) for PPV adj (high risk), 14% (95% CI: 9%-21%) for PPV adj (high/int risk), and 97% (95% CI: 96%-98%) for NPV adj with minimal inter-study heterogeneity ( I2 =79%, 21%, 0%, 0%, and 0%, respectively). Effect estimates of TSP-9 performance demonstrate that the test provides risk stratification for BE patients. The TSP-9 test can provide clinically impactful results to enable escalation of care for high-risk patients or to identify low-risk patients who can be safely managed with routine surveillance.
Publicações recentes
Recurrent Barrett's esophagus-related neoplasia is uncommon after successful endoscopic eradication therapy over long-term follow-up.
SOX9 protein in goblet cells as a critical mediator and potential therapeutic target in Barrett's esophagus: An integrated bioinformatics analysis.
Clinical Utility of Biomarkers for Barrett's Esophagus: Guidelines and Future Directions.
An early-stage adenocarcinoma originating from a 15-cm long-segment Barrett's esophagus: A case report.
[Prevalence of Barrett's esophagus and factors associated with the diagnosis of dysplasia or adenocarcinoma in patients evaluated at a Chilean university endoscopy center].
📚 EuropePMCmostrando 200
The Impact of Hiatus Hernia Size on Dysplasia Progression in Patients With Barrett's Esophagus.
JGH open : an open access journal of gastroenterology and hepatologyRecurrent Barrett's esophagus-related neoplasia is uncommon after successful endoscopic eradication therapy over long-term follow-up.
Diseases of the esophagus : official journal of the International Society for Diseases of the EsophagusAdjunctive Use of p53 Immunohistochemistry for Risk Stratification in Barrett's Esophagus: A Systematic Review and Meta-Analysis.
The American journal of gastroenterologySOX9 protein in goblet cells as a critical mediator and potential therapeutic target in Barrett's esophagus: An integrated bioinformatics analysis.
International journal of biological macromoleculesBarrett High-Grade Dysplasia and Early Esophageal Adenocarcinoma in Patients With Positive Results on a Nonendoscopic Methylated DNA Biomarker Test.
Gastroenterology & hepatologyCharacteristics and causes of post-endoscopy Barrett's neoplasia: Retrospective multicenter study.
Endoscopy international openClinical Utility of Biomarkers for Barrett's Esophagus: Guidelines and Future Directions.
Gastroenterology clinics of North AmericaAn early-stage adenocarcinoma originating from a 15-cm long-segment Barrett's esophagus: A case report.
MedicineThe Evolving Paradigm of Esophageal and Esophagogastric Junction Adenocarcinoma: Current Insights, Emerging Therapies, and Future Directions.
Journal of cancer science and clinical therapeutics[Prevalence of Barrett's esophagus and factors associated with the diagnosis of dysplasia or adenocarcinoma in patients evaluated at a Chilean university endoscopy center].
Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del PeruThe Impact of Neoadjuvant Chemoradiation Therapy on Non-Tumorous Barrett's Dysplasia of the Esophagus: A Multicenter Cohort Study.
Journal of clinical medicineCrypt Dysplasia is a Risk Factor for the Development of High-Grade Dysplasia/Adenocarcinoma in Barrett Esophagus.
The American journal of surgical pathologyA machine-learning informed circulating microbial DNA signature for early diagnosis of esophageal adenocarcinoma.
Gut microbesEvaluating the Efficacy and Safety of Radiofrequency Ablation Compared to Endoscopic Surveillance in Managing Low-Grade Dysplasia in Barrett's Esophagus: A Systematic Review and Meta-Analysis.
CureusEsophageal Function Testing Identifies Barrett's Esophagus Patients With Pathological Acid Exposure at Risk for Neoplasia.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationDurability of cryoballoon ablation for eradication of neoplastic Barrett's esophagus: a multicenter prospective cohort study (with video).
Gastrointestinal endoscopyRisk stratification for progression to adenocarcinoma and high-grade dysplasia in Barrett's esophagus: a cohort study from an expert Spanish center.
Revista espanola de enfermedades digestivasAI-Driven Risk Prediction Tool (TSP-9) Informs Risk-Aligned Care for Patients with Barrett's Esophagus.
Diagnostics (Basel, Switzerland)Cancer Burden on Piecemeal Endoscopic Resection of Early Adenocarcinoma in Barrett's Oesophagus Correlates With the Risk of Neoplastic Recurrence.
United European gastroenterology journalThe Tissue Systems Pathology Test Predicts Risk of Progression in Patients With Barrett's Esophagus: Systematic Review and Meta-Analysis.
Journal of clinical gastroenterologyResearch Communication: Prevalence of Asymptomatic Premalignant Oesophageal Lesions in Patients With Fanconi Anaemia.
Alimentary pharmacology & therapeuticsDiscovery and Validation of Molecular Biomarkers for Differentiation of Nondysplastic Barrett's Esophagus from High-grade Dysplasia and Esophageal Adenocarcinoma.
Cancer prevention research (Philadelphia, Pa.)Margin clearance and post-procedure ablation decrease recurrence risk in endoscopic mucosal resections for Barrett's-related neoplasia.
HistopathologyGlobal Hypomethylation as Minimal Residual Disease (MRD) Biomarker in Esophageal and Esophagogastric Junction Adenocarcinoma.
CancersPrecision Care in Screening, Surveillance, and Overall Management of Barrett's Esophagus.
Journal of personalized medicineIncreased reflux secondary bile acids are associated with changes to the microbiome and transcriptome in Barrett's esophagus.
Gut microbesCircumferential endoscopic submucosal dissection of a 14-cm long-segment Barrett's esophagus with multifocal adenocarcinoma: a case report.
VideoGIE : an official video journal of the American Society for Gastrointestinal EndoscopyTackling Prevention and Early Diagnosis of Esophageal Adenocarcinoma Through a National Barrett's Registry and Scientific Network.
Annals of surgeryEfficacy and Safety of Advanced Endoscopic Techniques in Early Barrett's Neoplasia: A Systematic Review and Pooled Analysis.
CureusLncRNA small nucleolar RNA host gene 1 (SNHG1) mediates acidic bile salt-induced EMT via the ULK1-Notch1 axis in Barrett's esophagus.
Molecular biomedicineDistal esophageal acid exposure and poor esophageal clearance correlate with probability of progression in Barrett's esophagus as determined by the tissue systems pathology test.
Surgical endoscopyEndoscopic mucosal resection for Barrett's neoplasia: Long-term outcomes from the largest Canadian single-center experience.
Endoscopy international openEndoscopic calcium electroporation in patients with precancerous cellular changes in the esophagus.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyBiomarker risk stratification with capsule sponge in the surveillance of Barrett's oesophagus: prospective evaluation of UK real-world implementation.
Lancet (London, England)Texture and Colour Enhancement Imaging versus White Light Endoscopy for Detection of Dysplasia within Barrett's Oesophagus: A Pilot Study.
DigestionCost-Effectiveness of Regular Surveillance Versus Endoscopy at Need for Patients With Barrett's Esophagus: Economic Evaluation Alongside the Barrett's Oesophagus Surveillance Study (BOSS) Randomized Controlled Trial.
GastroenterologyImpact on Barrett's dysplasia yield following the introduction of capsule sponge testing versus traditional endoscopic surveillance.
Diseases of the esophagus : official journal of the International Society for Diseases of the EsophagusL1 Capsid Protein Expression in HPV-Positive Barrett Metaplasia-Dysplasia-Adenocarcinoma Lesions.
Clinical and translational gastroenterologyIndefinite for dysplasia in Barrett's esophagus carries substantial risk for prevalent and incident neoplasia: updated outcomes and long-term follow-up.
Gastrointestinal endoscopyThe future is now: advancing p53 immunohistochemistry in Barrett's oesophagus and its implication for the everyday pathologist.
HistopathologyGastric (Foveolar)-Type Dysplasia in Barrett's Esophagus: A Clinical, Molecular, and Long-Term Outcome Study.
The American journal of gastroenterologyPrevalence of intestinal metaplasia, dysplasia, and esophageal adenocarcinoma in patients with irregular Z-line: a systematic review and meta-analysis.
Clinical endoscopyEvolution of Esophageal Adenocarcinoma From Precursor Lesion Stem Cells.
GastroenterologyNeutrophil-Lymphocyte Ratio May be Used as a Biomarker for Predicting Progression of Barrett's Esophagus to Esophageal Adenocarcinoma: A Retrospective Cohort Study.
JGH open : an open access journal of gastroenterology and hepatologyEfficacy and safety of H-APC in Barrett's esophagus: Italian prospective multicenter study.
Endoscopy international openNatural course of high-grade dysplasia in Barrett's esophagus: a scoping review and case series.
Gastrointestinal endoscopySurveillance of Barrett's Esophagus Patients in an Expert Center is Associated With Low Disease-Specific Mortality.
United European gastroenterology journalSpatiotemporal Study of a Risk-Stratification Epigenetic-Based Biomarker Assay in Patients With Barrett Esophagus.
The American journal of gastroenterologyDiscovery of Methylated DNA Biomarkers for Potential Nonendoscopic Detection of Barrett's Esophagus and Esophageal Adenocarcinoma.
The American journal of gastroenterologyHistological features indicate the risk of progression of patients with Barrett's esophagus.
Pathology, research and practiceProgression to cancer in patients with confirmed dysplasia compared to dysplasia downgraded to non-dysplastic metaplasia in Barrett's esophagus: a retrospective cohort study in Sweden.
Clinical endoscopyNeoplastic Progression Risk in Females With Barrett's Esophagus: A Systematic Review and Meta-Analysis of Individual Patient Data.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationAnalytical Validation of Esopredict, an Epigenetic Prognostic Assay for Patients with Barrett's Esophagus.
Diagnostics (Basel, Switzerland)Narrow band imaging: Important tool for early diagnosis, management, and improved outcomes in gastrointestinal lesions.
World journal of surgeryOutcomes of patients with Barrett's oesophagus with low-grade dysplasia undergoing endoscopic surveillance in a tertiary centre: a retrospective cohort study.
Internal medicine journalThe Association Between Obesity and Malignant Progression of Barrett's Esophagus: A Systematic Review and Dose-Response Meta-Analysis.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationRecurrence following successful eradication of neoplasia with endoscopic mucosal resection compared with endoscopic submucosal dissection in Barrett's esophagus: a retrospective comparison.
EndoscopyCan optical evaluation distinguish between T1a and T1b esophageal adenocarcinoma: an international expert interobserver agreement study.
EndoscopyValidation of an Epigenetic Prognostic Assay to Accurately Risk-Stratify Patients With Barrett Esophagus.
The American journal of gastroenterology[Barrett's Esophagus: Update on the Diagnosis and Treatment. Review].
Revista medica de ChileIrregular Z-Line: To Biopsy or Not to Biopsy?
Digestive diseases and sciencesSteroid lifting method during endoscopic submucosal dissection: A novel strategy for stricture prevention.
DEN openPreinjection With Ligation-Assisted Endoscopic Mucosal Resection for Barrett's Dysplasia and Early Esophageal Adenocarcinoma: Characteristic Histological Features of the Depth of Resection.
Journal of clinical gastroenterologyThe Aberrant Expression of Biomarkers and Risk Prediction for Neoplastic Changes in Barrett's Esophagus-Dysplasia.
CancersDesign and Evaluation of ScanCap: A Low-Cost, Reusable Tethered Capsule Endoscope with Blue-Green Illumination Imaging for Unsedated Screening and Early Detection of Barrett's Esophagus.
Bioengineering (Basel, Switzerland)AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett's Esophagus and Related Neoplasia.
GastroenterologyOesophageal cell collection device and biomarker testing to identify high-risk Barrett's patients requiring endoscopic investigation.
The British journal of surgeryMulticenter, Prospective Trial of Nonendoscopic Biomarker-Driven Detection of Barrett's Esophagus and Esophageal Adenocarcinoma.
The American journal of gastroenterologySafety and efficacy of salvage endoscopic submucosal dissection for Barrett's neoplasia recurrence after radiofrequency ablation.
EndoscopyTrends in prevalence of esophageal adenocarcinoma: Findings from a statewide database of over 6 million patients.
Endoscopy international openCDKN2A-p16 Deletion and Activated KRASG12D Drive Barrett's-Like Gland Hyperplasia-Metaplasia and Synergize in the Development of Dysplasia Precancer Lesions.
Cellular and molecular gastroenterology and hepatologyLiquid nitrogen spray cryotherapy for eradication of dysplastic Barrett's esophagus: results from a multicenter prospective registry.
Gastrointestinal endoscopyVariation in proliferative and cell cycle markers in Barrett's esophagus in relation to circumferential and axial location in the esophagus.
European journal of gastroenterology & hepatologyIncidence rates of Barrett's esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis.
iGIE : innovation, investigation and insightsFeasibility Study Utilizing NanoString's Digital Spatial Profiling (DSP) Technology for Characterizing the Immune Microenvironment in Barrett's Esophagus Formalin-Fixed Paraffin-Embedded Tissues.
CancersThe Salivary Microbiome and Predicted Metabolite Production Are Associated with Barrett's Esophagus and High-Grade Dysplasia or Adenocarcinoma.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyWATS 3D : An Interobserver Study of Barrett's Esophagus-Associated Dysplasia Among Gastrointestinal Pathologists.
Clinical and translational gastroenterologySignificance of Crypt Atypia in Barrett's Esophagus: A Clinical, Molecular, and Outcome Study.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationThe impact of endoscopic treatment on health-related quality of life in patients with Barrett's neoplasia: a scoping review.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitationDiagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.
EndoscopySignificant Reduction in the Diagnosis of Barrett's Esophagus and Related Dysplasia During the COVID-19 Pandemic.
The American journal of gastroenterologyA Randomized Controlled Study on Clinical Adherence to Evidence-Based Guidelines in the Management of Simulated Patients With Barrett's Esophagus and the Clinical Utility of a Tissue Systems Pathology Test: Results From Q-TAB.
Clinical and translational gastroenterologyThe Tissue Systems Pathology Test Outperforms Pathology Review in Risk Stratifying Patients With Low-Grade Dysplasia.
GastroenterologyOptimizing Storage and Computational Efficiency: An Efficient Algorithm for Whole Slide Image Size Reduction.
Mayo Clinic proceedings. Digital healthA Tissue Systems Pathology Test Outperforms the Standard-of-Care Variables in Predicting Progression in Patients With Barrett's Esophagus.
Clinical and translational gastroenterologyImpact of Residing in Below Median Household Income Districts on Outcomes in Patients with Advanced Barrett's Esophagus.
Journal of the Canadian Association of GastroenterologyImpact of race/ethnicity and socioeconomic status on incident and prevalent esophageal cancer in patients with Barrett's esophagus.
Diseases of the esophagus : official journal of the International Society for Diseases of the EsophagusThe Salivary Microbiome and Predicted Metabolite Production are Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma.
bioRxiv : the preprint server for biologyRole of Confocal Laser Endomicroscopy in Early Detection of Upper Gastrointestinal Malignancy in High Risk Patients.
Asian Pacific journal of cancer prevention : APJCPFibroblast Activation Protein-α (FAP) Identifies Stromal Invasion in Colorectal Neoplasia.
The American journal of surgical pathologyLong-term outcomes following successful endoscopic treatment of T1 esophageal adenocarcinoma: a multicenter cohort study.
Gastrointestinal endoscopyNON-ENDOSCOPIC ESOPHAGEAL SAMPLING DEVICE AND BIOMARKER PANEL FOR DETECTION OF BARRETT'S ESOPHAGUS (BE) AND ESOPHAGEAL ADENOCARCINOMA (EAC).
medRxiv : the preprint server for health sciencesAn Automated Tissue Systems Pathology Test Can Standardize the Management and Improve Health Outcomes for Patients With Barrett's Esophagus.
The American journal of gastroenterologyMagnitude and Time-Trends of Post-Endoscopy Esophageal Adenocarcinoma and Post-Endoscopy Esophageal Neoplasia in a Population-Based Cohort Study: The Nordic Barrett's Esophagus Study.
GastroenterologyNeoplastic Progression of Barrett's Esophagus Among Organ Transplant Recipients: a Retrospective Cohort Study.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractDegree of crypt atypia correlates with progression to high-grade dysplasia/adenocarcinoma in non-dysplastic Barrett's oesophagus.
HistopathologyCost-effectiveness Analysis of Radiofrequency Ablation in Patients With Barrett Esophagus and High-grade Dysplasia or Low-grade Dysplasia.
Clinical therapeuticsWhat Is "Cold" and What Is "Hot" in Mucosal Ablation for Barrett's Oesophagus-Related Dysplasia: A Practical Guide.
Life (Basel, Switzerland)Seattle Protocol Is More Effective in Detection of Dysplasia Compared to Technology-Assisted Targeted Biopsies in Patients with Barrett's Esophagus.
Journal of clinical medicineExtrachromosomal DNA in the cancerous transformation of Barrett's oesophagus.
NatureReal-world upper endoscopy utilization patterns among patients with gastroesophageal reflux disease, Barrett esophagus, and Barrett esophagus-related esophageal neoplasia in the United States.
MedicineReal-world evidence of safety and effectiveness of Barrett's endoscopic therapy.
Gastrointestinal endoscopyHealthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett's Esophagus, and Barrett's Esophagus-Related Neoplasia in the United States.
Journal of health economics and outcomes researchRadio frequency ablation of dysplastic Barrett's esophagus: Outcomes of a single-center registry.
Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society[Current status in Barrett's esophagus].
Deutsche medizinische Wochenschrift (1946)The effect of procedural time on dysplasia detection rate during endoscopic surveillance of Barrett's esophagus.
EndoscopyClinical consequences of nonadherence to Barrett's esophagus surveillance recommendations: a Multicenter prospective cohort study.
Diseases of the esophagus : official journal of the International Society for Diseases of the EsophagusDevelopment and validation of a prediction model for histologic progression in patients with nondysplastic Barrett's esophagus.
Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy SocietyAdvancements in photodynamic therapy of esophageal cancer.
Frontiers in oncologyLong-term fear of cancer recurrence in patients treated endoscopically for early Barrett's neoplasia.
Diseases of the esophagus : official journal of the International Society for Diseases of the EsophagusSafety and efficacy of liquid nitrogen spray cryotherapy in Barrett's neoplasia - a comprehensive review and meta-analysis.
Endoscopy international openUtility of wide-area transepithelial sampling with 3-dimensional computer-assisted analysis as an adjunct to forceps biopsy sampling in the surveillance of patients with Barrett's esophagus after endoscopic eradication therapy.
iGIE : innovation, investigation and insightsUtilization trends for endoscopic ablation therapy and esophagectomy in Barrett's esophagus from 2005 to 2019.
Scientific reportsAberrant p53 expression is associated with neoplastic progression in Barrett oesophagus diagnosed as indefinite for dysplasia.
HistopathologyLow-grade dysplasia in Barrett's esophagus: A problematic diagnosis.
Gastroenterologia y hepatologiaHigh proficiency of esophageal endoscopic submucosal dissection with a "tunnel + clip traction" strategy: a large French multicentric study.
Surgical endoscopyA Consensus Diagnosis Utilizing Surface KI-67 Expression as an Ancillary Marker in Low-Grade Dysplasia Helps Identify Patients at High Risk of Progression to High-Grade Dysplasia and Esophaegal Adenocarcinoma.
Diseases of the esophagus : official journal of the International Society for Diseases of the EsophagusSerological levels of IGF-1 and IGFBP-3 in patients with Barrett's esophagus and esophageal adenocarcinoma: Longitudinal study.
Gastroenterologia y hepatologiaManagement of Dysplastic Barrett's Esophagus and Early Esophageal Adenocarcinoma.
Gastroenterology clinics of North AmericaBarrett's oesophagus with indefinite for dysplasia shows high rates of prevalent and incident neoplasia in a UK multicentre cohort.
Journal of clinical pathologyWide-area transepithelial sampling with computer-assisted analysis to detect high grade dysplasia and cancer in Barrett's esophagus: a multicenter randomized study.
EndoscopyUsing Natural Language Processing to Automatically Identify Dysplasia in Pathology Reports for Patients With Barrett's Esophagus.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationCharacterizing isoform switching events in esophageal adenocarcinoma.
Molecular therapy. Nucleic acidsBarrett esophagus frequency and predictors of dysplasia or cancer in Barrett esophagus.
European review for medical and pharmacological sciencesIncreased PXR and Suppressed T-Cell Signaling Are Associated With Malignant Degeneration of Barrett's Esophagus.
Gastro hep advancesDiagnostic Accuracy of Artificial Intelligence (AI) to Detect Early Neoplasia in Barrett's Esophagus: A Non-comparative Systematic Review and Meta-Analysis.
Frontiers in medicineSex Differences in Neoplastic Progression in Barrett's Esophagus: A Multicenter Prospective Cohort Study.
CancershERG1 Potassium Channel Expression in Colorectal Adenomas: Comparison with Other Preneoplastic Lesions of the Gastrointestinal Tract.
Current issues in molecular biologyDevelopment of a deep learning model for the histologic diagnosis of dysplasia in Barrett's esophagus.
Gastrointestinal endoscopyThe concordance between wide-area transepithelial sampling with computer-assisted 3-dimensional analysis (WATS-3D) and standard endoscope biopsy in the detection of Barrett's esophagus and esophageal dysplasia.
Annals of diagnostic pathologyDeciphering the Immune Complexity in Esophageal Adenocarcinoma and Pre-Cancerous Lesions With Sequential Multiplex Immunohistochemistry and Sparse Subspace Clustering Approach.
Frontiers in immunologyLaparoscopic total fundoplication is superior to medical treatment for reducing the cancer risk in Barrett's esophagus: a long-term analysis.
Diseases of the esophagus : official journal of the International Society for Diseases of the EsophagusPredictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett's esophagus: a matched case-control study.
Virchows Archiv : an international journal of pathologyA personalized and dynamic risk estimation model: The new paradigm in Barrett's esophagus surveillance.
PloS oneRisk of progression in Barrett's esophagus based on diagnoses of general and gastrointestinal pathologists. A retrospective case-control study from Northern and Central Finland.
Scandinavian journal of gastroenterology[Endoscopic Interventional Treatment of Precancerous Lesions and Early Carcinoma of the Esophagus - Criteria and Techniques of Local Ablation and Resection].
Therapeutische Umschau. Revue therapeutique[GERD and Barett: Natural Course of One Disease - Update Diagnostics and Therapy].
Therapeutische Umschau. Revue therapeutiqueSurveillance After Treatment of Barrett's Esophagus Benefits Those With High-Grade Dysplasia or Intramucosal Cancer Most.
The American journal of gastroenterologySurveillance of Barrett's esophagus using wide-area transepithelial sampling: systematic review and meta-analysis.
Endoscopy international openAdherence to Surveillance Endoscopies Posteradication of Barrett's Esophagus With High-grade Dysplasia or Carcinoma In Situ.
Journal of clinical gastroenterologyDiagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline.
The American journal of gastroenterologyBarrett's esophagus: Review of natural history and comparative efficacy of endoscopic and surgical therapies.
World journal of gastrointestinal oncologyBarrett's esophagus: results from an Italian cohort with tight endoscopic surveillance.
Acta bio-medica : Atenei ParmensisDysplastic Recurrence After Successful Treatment for Early Barrett's Neoplasia: Development and Validation of a Prediction Model.
GastroenterologyDetection of Barrett's neoplasia with a near-infrared fluorescent heterodimeric peptide.
EndoscopyDevelopment and External Validation of a Model to Predict Complex Treatment After Radiofrequency Ablation for Barrett's Esophagus With Early Neoplasia.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationThe utility of P53 immunohistochemistry in the diagnosis of Barrett's oesophagus with indefinite for dysplasia.
Histopathology[Management of complicated Barrett's esophagus. Observational study carried out in a regional hospital].
Revue medicale de LiegeOptimized Surveillance Intervals Following Endoscopic Eradication of Dysplastic Barrett's Esophagus: An International Cohort Study.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationPrediction of Progression in Barrett's Esophagus Using a Tissue Systems Pathology Test: A Pooled Analysis of International Multicenter Studies.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationEndoscopic eradication therapy for Barrett's esophagus-related neoplasia: a final 10-year report from the UK National HALO Radiofrequency Ablation Registry.
Gastrointestinal endoscopyExpression of DNA Mismatch Repair Proteins, PD1 and PDL1 in Barrett's Neoplasia.
Cancer genomics & proteomicsRisk of esophageal adenocarcinoma in patients with Barrett's esophagus using proton pump inhibitors: a systematic review with meta-analysis and sequential trial analysis.
Translational cancer researchImpact of expert center endoscopic assessment of confirmed low grade dysplasia in Barrett's esophagus diagnosed in community hospitals.
EndoscopyPrediction of neoplastic progression in Barrett's esophagus using nanoscale nuclear architecture mapping: a pilot study.
Gastrointestinal endoscopyRecommendations for endoscopic surveillance after esophageal atresia repair in adults.
Diseases of the esophagus : official journal of the International Society for Diseases of the EsophagusUse of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot.
The Lancet. OncologyExternal validation of a model determining risk of neoplastic progression of Barrett's esophagus in a cohort of U.S. veterans.
Gastrointestinal endoscopyBenefit of radiofrequency ablation after widespread endoscopic resection of neoplastic Barrett's esophagus in daily practice.
Annals of gastroenterologyBenefit, tolerance, and safety of hybrid argon plasma coagulation for treatment of Barrett's esophagus: US pilot study.
Endoscopy international openMulticenter randomized controlled trial comparing forceps biopsy sampling with wide-area transepithelial sampling brush for detecting intestinal metaplasia and dysplasia during routine upper endoscopy.
Gastrointestinal endoscopyTargeted Hsp70 fluorescence molecular endoscopy detects dysplasia in Barrett's esophagus.
European journal of nuclear medicine and molecular imagingProton pump inhibitors may reduce the risk of high-grade dysplasia and/or esophageal adenocarcinoma in Barrett's esophagus: a systematic review and meta-analysis.
Expert review of clinical pharmacologyPrevalence of Barrett's esophagus in a Southern European country: a multicenter study.
European journal of gastroenterology & hepatologyGender differences in Barrett's esophagus and progression of disease: a systematic review and meta-analysis.
Diseases of the esophagus : official journal of the International Society for Diseases of the EsophagusAbnormal TP53 Predicts Risk of Progression in Patients With Barrett's Esophagus Regardless of a Diagnosis of Dysplasia.
GastroenterologyPredictors of recurrence of dysplasia or cancer in patients with dysplastic Barrett's esophagus following complete eradication of dysplasia: a single-center retrospective cohort study.
Surgical endoscopyMachine learning for grading and prognosis of esophageal dysplasia using mass spectrometry and histological imaging.
Computers in biology and medicineExtending treatment criteria for Barrett's neoplasia: results of a nationwide cohort of 138 endoscopic submucosal dissection procedures.
EndoscopyThe natural history of low-grade dysplasia in Barrett's esophagus and risk factors for progression.
JGH open : an open access journal of gastroenterology and hepatologyVideoconference microscopy is a reliable alternative to conventional microscopy in the evaluation of Barrett's esophagus: Zooming into a new era.
Diseases of the esophagus : official journal of the International Society for Diseases of the EsophagusWide-area transepithelial sampling for dysplasia detection in Barrett's esophagus: a systematic review and meta-analysis.
Gastrointestinal endoscopyProgression of Barrett's esophagus, crypt dysplasia, and low-grade dysplasia diagnosed by wide-area transepithelial sampling with 3-dimensional computer-assisted analysis: a retrospective analysis.
Gastrointestinal endoscopyNonthermal resection device for ablation of Barrett's esophagus: a feasibility and safety study.
EndoscopyGenetic profiles of Barrett's esophagus and esophageal adenocarcinoma in Japanese patients.
Scientific reportsEndoscopic submucosal dissection vs. endoscopic mucosal resection for early Barrett's neoplasia in the West: a retrospective study.
EndoscopyNot all low grade dysplasia in Barrett's oesophagus is the same: using specific histological criteria in predicting progression to neoplasia.
PathologySystematic review with meta-analysis: the effects of family history on the risk of Barrett's oesophagus and oesophageal adenocarcinoma.
Alimentary pharmacology & therapeuticsSystematic review with meta-analysis: neoplasia detection rate and post-endoscopy Barrett's neoplasia in Barrett's oesophagus.
Alimentary pharmacology & therapeuticsDiagnostic Performance of Artificial Intelligence-Based Models for the Detection of Early Esophageal Cancers in Barret's Esophagus: A Meta-Analysis of Patient-Based Studies.
CureusBarrett's esophagus surveillance in a prospective Dutch multi-center community-based cohort of 985 patients demonstrates low risk of neoplastic progression.
United European gastroenterology journalSystematic review with meta-analysis: the long-term efficacy of Barrett's endoscopic therapy-stringent selection criteria and a proposal for definitions.
Alimentary pharmacology & therapeuticsEvolution of re-epithelialization postcircumferential esophageal endoscopic submucosal dissection.
VideoGIE : an official video journal of the American Society for Gastrointestinal EndoscopyPersistent or recurrent Barrett's neoplasia after an endoscopic therapy session is associated with DNA content abnormality and can be detected by DNA flow cytometric analysis of paraffin-embedded tissue.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, IncImpact of bariatric surgery on surveillance and treatment outcomes of Barrett's esophagus: A stage-matched cohort study.
Surgery for obesity and related diseases : official journal of the American Society for Bariatric SurgeryIncidence and outcomes of poor healing and poor squamous regeneration after radiofrequency ablation therapy for early Barrett's neoplasia.
EndoscopyEpidemiology of Barrett's Esophagus and Esophageal Carcinoma.
The Surgical clinics of North AmericaBarrett's esophagus with low-grade dysplasia: high rate of upstaging at Barrett's esophagus referral units suggests progression rates may be overestimated.
Gastrointestinal endoscopyLiquid nitrogen spray cryotherapy for intramucosal carcinoma and extensive gastric intestinal metaplasia with dysplasia.
VideoGIE : an official video journal of the American Society for Gastrointestinal EndoscopyTissue Systems Pathology Test Objectively Risk Stratifies Barrett's Esophagus Patients With Low-Grade Dysplasia.
The American journal of gastroenterologyTaking the Next Steps in Endoscopic Visual Assessment of Barrett's Esophagus: A Pilot Study.
Clinical and experimental gastroenterologyMagnitude and Time-Trend Analysis of Postendoscopy Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationPrevalence and Predictors of Missed Dysplasia on Index Barrett's Esophagus Diagnosing Endoscopy in a Veteran Population.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationRandomized Controlled Trial of the Gastrin/CCK2 Receptor Antagonist Netazepide in Patients with Barrett's Esophagus.
Cancer prevention research (Philadelphia, Pa.)Loss of SMAD4 Is Sufficient to Promote Tumorigenesis in a Model of Dysplastic Barrett's Esophagus.
Cellular and molecular gastroenterology and hepatologyPost-ablation buried neoplasia in Barrett's esophagus.
Scandinavian journal of gastroenterologyLong-term outcomes after endoscopic treatment for Barrett's neoplasia with radiofrequency ablation ± endoscopic resection: results from the national Dutch database in a 10-year period.
GutTissueCypher Barrett's esophagus assay impacts clinical decisions in the management of patients with Barrett's esophagus.
Endoscopy international openLongitudinal and Circumferential Distributions of Dysplasia and Early Neoplasia in Barrett's Esophagus: A Pooled Analysis of Three Prospective Studies.
Clinical and translational gastroenterologyDo proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis.
Journal of cancer research and clinical oncologyAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Displasia de alto grau em doentes com esôfago de Barrett.
É de uma associação que acompanha esta doença? Fale com a gente →
Doença com base genética
Um médico geneticista pode ajudar no diagnóstico de Displasia de alto grau em doentes com esôfago de Barrett e no aconselhamento genético da família.
Doenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Perguntas frequentes
O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu
É uma situação clínica particular caracterizada por alterações nas células do revestimento do esôfago em pacientes que já apresentam esôfago de Barrett. No sistema internacional de doenças, é identificada pelo código ORPHA:231080 e pelo CID-10 K22.7.
Referências
Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete
3 fontes citadas no texto · 9 publicações do grafo RarasNet (PubMed) · 1 base de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Citar este verbete
Raras. (2026). Displasia de alto grau em doentes com esôfago de Barrett. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/displasia-de-alto-grau-em-doentes-com-esofago-de-barrett
Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
Displasia de alto grau em doentes com esôfago de Barrett
📋 Origem dos dados
Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.
- Doença rara (ontologia)
- fonte: Orphanet
- Codificação WHO/SUS
- fonte: WHO ICD-10 / DATASUS
- CID-11 (futuro)
- fonte: WHO ICD-11
- Medicamentos aprovados FDA
- fonte: FDA OpenFDA